Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aqueous humor cytokine changes after intravitreal brolucizumab in neovascular age-related macular degeneration
TCTR20220511001Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Feb 2023
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Change in cytokine levels. Started Feb 2023; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on TCTR20220511001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220511001.